ELUT vs NVCR vs XTNT vs MDT vs HOLX

For growth investors, Xtant Medical Holdings, Inc.

(XTNT) is the stronger pick with 28. 4% revenue growth year-over-year, versus -49. 6% for Elutia Inc. (ELUT). Elutia Inc. (ELUT) offers the better valuation at 0. 8x trailing P/E, making it the more compelling value choice. Analysts rate NovoCure Limited (NVCR) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Elutia Inc.

(ELUT) is the cheapest at 0. 8x versus Hologic, Inc. at 30. 5x. On forward P/E, Medtronic plc is actually cheaper at 14. 1x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Hologic, Inc.

(HOLX) delivered a total return of +15. 8%, compared to -91. 4% for Elutia Inc. (ELUT). Over 10 years, the gap is even starker: HOLX returned +124. 3% versus XTNT's -97. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Elutia Inc.

(ELUT) is the lower-risk stock at -0. 11β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately -2170% more volatile than ELUT relative to the S&P 500. On balance sheet safety, Elutia Inc. (ELUT) carries a lower debt/equity ratio of 27% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Xtant Medical Holdings, Inc.

(XTNT) is pulling ahead at 28. 4% versus -49. 6% for Elutia Inc. (ELUT). On earnings-per-share growth, the picture is similar: Elutia Inc. grew EPS 169. 4% year-over-year, compared to -25. 0% for Hologic, Inc.. Over a 3-year CAGR, XTNT leads at 28. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Elutia Inc.

(ELUT) is the more profitable company, earning 434. 2% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 434. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MDT leads at 17. 8% versus -149. 8% for ELUT. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Medtronic plc (MDT) trades at 14.

1x forward P/E versus 17. 2x for Hologic, Inc. — 3. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 99. 0% to $33. 50.

In this comparison, MDT (3.

6% yield) pays a dividend. ELUT, NVCR, XTNT, HOLX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Medtronic plc (MDT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

47), 3. 6% yield). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MDT: +26. 5%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ELUT is a small-cap deep-value stock; NVCR is a small-cap quality compounder stock; XTNT is a small-cap high-growth stock; MDT is a mid-cap income-oriented stock; HOLX is a mid-cap quality compounder stock. MDT pays a dividend while ELUT, NVCR, XTNT, HOLX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.